Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to
innovate to transform the lives of patients and their families. We are
dedicated to developing potentially life-changing medicines for people with
serious diseases—often with limited or no therapeutic options. We have a
diverse portfolio of marketed medicines and novel product candidates, from
early- to late-stage development, in neuroscience and oncology. Within these
therapeutic areas, we are identifying new options for patients by actively
exploring small molecules and biologics, and through innovative delivery
technologies and science.
long-time leader in sleep medicine, Jazz has been at the forefront of providing
therapies and support for our patients living with serious, debilitating
neurologic disorders. More recently we have expanded into additional disease
areas with high unmet needs, including rare, severe childhood-onset epilepsies,
through our acquisition of GW Pharmaceuticals – which has pioneered science for
over two decades to bring regulatory-approved therapeutic options to support
patients and their families.
to expand our understanding of the brain, investigating therapies to treat
disorders in neurology and neuropsychiatry. Using our world-leading
research platform, we plan to explore how this, combined with our other
world-class proprietary programmes, can unlock much-needed solutions for even
headquartered in Dublin, Ireland and has employees around the globe, serving
patients in nearly 75 countries.
Be sure to
catch the Sponsor-led Satellite Session on 11 October at 16:15 in the main